NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05744297

Acronym

ActiNG

Enrollment

Registered

2023-02-27

Start date

2023-04-28

Completion date

2023-10-31

Last updated

2023-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout Arthritis

Brief summary

Gout is a chronic joint disease associated with deposition of monosodium urate crystals, as a consequence of hyperuricemia. Gout is an intermittent flaring condition and acute gout flares are driven by NLRP3 inflammasome and IL1-beta production. However pathogenesis of acute gout flares remains poorly known in vivo in human. The aim of this study is to evaluate NLRP3 inflammasome activation in vivo in patients cells during acute gout flares.

Detailed description

Blood and synovial fluid will be obtained from remainder of patients' samples during an acute gout flares. White blood cells will be isolated and NLRP3 inflammasome activation will be assessed. Then, NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Hospitalization for acute gout flare confirmed by joint fluid analysis or Nijmegen score \> 8 * Aged \> 18

Exclusion criteria

* Gout treatment already started * Inflammatory Arthritis other than Gout Arthritis * Pregnant or breast feeding women * Patient protected by law

Design outcomes

Primary

Measure	Time frame	Description
NLRP3 inflammasome activation in white blood cells.	Patient admission at hospital	White blood cells will be isolated from blood sample and NLRP3 inflammasome activation will be assessed by flow cytometry.

Secondary

Measure	Time frame	Description
NLRP3 inflammasome activation in synovial cells.	Patient admission at hospital	Nucleated cells will be isolated from synovial fluid sample and NLRP3 inflammasome activation will be assessed by flow cytometry.
Effects of NLRP3 inflammasome inhibitors on proportion of NLRP3 inflammasome activation in white blood cells/synovial cells	up to 7 days after analysis of NLRP3 activity	NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity in blood or synovial fluid.

Countries

France

Contacts

Primary ContactJulien Seiller, MD

jseiller@chsjsl.fr478 617 757

Outcome results